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Summary
The main proteinaceous component of the keratohyalin granules within the gran-
ular layer keratinocytes of the epidermis is the giant, repetitive polyprotein profi-
laggrin. When granular layer cells commit to terminal differentiation to form the
flattened squames of the stratum corneum, profilaggrin is rapidly cleaved into
multiple copies of the 37 kDa filaggrin monomer, which binds to and condenses
the keratin cytoskeleton, thereby facilitating cellular compression. Within the
stratum corneum, filaggrin is broken down to form natural moisturising factor, a
pool of amino acids and derivatives thereof that exerts multiple effects. Filaggrin
is therefore essential for normal stratum corneum biogenesis and physiology. In
2006, the McLean group identified the first loss-of-function mutations in the
filaggrin gene (FLG) as the cause of the common monogenic genodermatosis
ichthyosis vulgaris (IV). In parallel, they showed by multiple methods that
these mutations, carried by up to 10% of various human populations are the
major genetic predisposing factor for atopic dermatitis (eczema) and all of the
associated allergic phenotypes that constitute the atopic diathesis. This paradigm-
shifting work showed that skin barrier deficiency is a major early event in the
pathophysiology of eczema and allergy.
What is already known?
• Filaggrin is a critically important, multifunctional protein required for the normal
biogenesis and physiology of the stratum corneum.
What does (recent) work tell us?
• Loss-of-function mutations in the filaggrin gene are common in the human popu-
lation and cause clinically dry skin, ichthyosis vulgaris and importantly, are a major
genetic predisposing factor for atopic dermatitis and its associated allergic condi-
tions. This work revealed that skin barrier deficiency is the major pathomechanism
underlying atopic disease.
Ichthyosis vulgaris (IV) – a dry flaky skin condition fre-
quently seen by all dermatologists – is arguably the most
common monogenic hereditary skin disorder.1 Despite there
being a body of biochemical and genetic mapping literature
dating from the 1980s suggesting that some kind of defect
in the skin barrier protein filaggrin might be involved in
the pathophysiology of IV, no genetic defect had been
identified to confirm or disconfirm this until some 20 years
later.
The reason behind this lack of progress stems from the
structure of this highly complicated protein and the very unu-
sual gene that encodes it.2 The name filaggrin is a contraction
of ‘filament aggregating protein’. The protein was originally
identified and named by Beverly Dale in Seattle as an insoluble
protein that binds keratin proteins.3,4 Cell culture experiments
showed that fluorescently-labelled filaggrin is able to decorate
keratin intermediate filaments4 and in addition, in vitro experi-
ments showed that filaggin causes bundling and condensation
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of these filaments.5 Immunohistochemistry, immuno-electron
microscopy and further biochemical studies revealed that the
precursor of filaggrin, a giant (>400 kDa) protein known as
profilaggrin, is the main constituent of the keratohyalin gran-
ules that mark out the granular layer of the epidermis.2 The
fact that these granules are visible by low-power light micro-
scopy in H&E-stained skin sections is evidence that profilag-
grin/filaggrin is a very highly abundant protein in the
outermost layers of the epidermis. Molecular cloning of frag-
ments of the profilaggrin mRNA and gene revealed that this
encodes multiple copies of the 37 kDa filaggrin protein.
Human profilaggrin consists of 10–12 near-identical repeats of
the filaggrin monomer connected by short cleavable linkers –
somewhat resembling a string of sausages (Fig. 1).
The proprotein is inactive within the keratohyalin granules
but at the point during the epidermal differentiation pro-
gramme where granular layer keratinocytes commit to form-
ing the squames of the stratum corneum, these granules
vanish as profilaggin is rapidly processed into free filaggrin
monomers. This process is thought to condense the cytoskele-
ton and facilitate flattening of the terminally differentiating
granular cells into squames. A complex cascade of phos-
phatases and proteases is involved in this rapid degranulation
event.2 Within the squames, filaggrin undergoes further chem-
ical modification and proteolytic processing to eventually bro-
ken down completely to become natural moisturizing factor
(NMF) – a pool of hygroscopic amino acids and derivatives
thereof that act as a natural humectant within the residual
cytoplasmic space of the squames.2 NMF is perhaps an overly
simplistic misnomer, as this material appears to have several
interrelated functions including UV protection, modulating
stratum corneum pH and water retention, each of which
probably mediates other secondary effects.2 Overall, this is an
important polypeptide component for the biogenesis and nor-
mal function of the skin barrier layers.
The profilaggin/filaggrin gene (FLG), has 3 exons and is
bizarre in its sequence organisation (Fig. 1). The giant profi-
laggrin protein is encoded almost entirely by the enormous
third exon and because this consists of several near-identical
tandem repeats of the filaggrin sequence, it was one of the last
genes to be fully sequenced and assembled in the late stages
of the Human Genome Project. The gene remains particularly
poorly assembled and badly annotated across the many other
mammalian genomes that are now available. Due to its repeti-
tive nature, the gene is difficult to amplify by PCR and espe-
cially challenging to routinely re-sequence for detection of
pathogenic sequence variants. Even the Next-Generation
Sequencing (NGS) techniques currently in use struggle to
analyse FLG fully and reliably.
In 2005, my laboratory, in close collaboration with Alan
Irvine in Dublin and Phil Fleckman in Seattle, set about analys-
ing the FLG gene for the purpose of identifying putative muta-
tions in IV patients. One large IV family obtained from the
Fleckman group had been used previously to show genetic
linkage between polymorphic markers in the vicinity of the
FLG gene and transmission of the disease through the genera-
tions of pedigree.6 Very confusingly, however, these data gave
statistically significant linkage in that family when the disease
was modelled either as a recessive condition or as a domi-
nantly inherited trait. Normally, this should give a positive
result in one model but not the other. Alan Irvine identified
several Irish kindreds with IV, which crucially, his clinical
team very carefully examined and phenotyped for our studies.
Using methods that we had previously developed to clone
and sequence another large and unusually repetitive gene,
plectin – the causative gene for epidermolysis bullosa simplex
with muscular dystrophy and some other rare skin blistering
conditions,7,8 we were able to develop a strategy to sequence
part of the filaggrin gene initially.9 In both the US kindred
and in some of the Irish IV families, we identified the same
nonsense mutation (R501X – arginine codon 501 mutated to
a stop codon). However, in the US family, the mutation did
not fully segregate with the disease and this suggested that
there might be a second, as yet undetected, mutation. Using a
combination of techniques and with a fair measure of good
fortune, we were able to identify a second mutation in the
FLG gene
Protein domains encoded
10-12 near-perfect 324 amino acid repeats
2 imperfect repeats
15 351pb bp 12·7 kb (or variant alleles of 13·7 kb or 14·7 kb)
Figure 1. Schematic of the human profilaggrin/filaggrin gene (FLG) showing the very unusual intron-exon organisation (top), colour-coded to
show of this encodes the profilaggrin protein domains (bottom). The repetitive nature of this gene and protein impeded identification of the very
common FLG mutations for some decades.
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American family, known as 2282del4 (a 4 bp deletion leading
to a premature stop codon). Both the R501X and 2282del4
mutations truncate the profilaggrin protein within the first
filaggrin repeat and so effectively ‘knock out’ the gene/protein
more or less completely.
In human genetics, when one identifies a mutation for the
first time, it is standard practice to exclude this mutation from
50 normal population controls. When we did this for the FLG
mutations, to our great surprise, these were found at a high
frequency in the co-called normal population. Together, these
mutations are carried in the heterozygous state by about 9%
of the UK and Irish populations, with similar high frequencies
in other populations of white Caucasian ancestry.9,10 Very
careful clinical ascertainment of the skin phenotype in several
IV families in which these mutations segregate by the Irvine
group revealed that the heterozygous carriers have a subtle
sub-clinical IV phenotype with dry skin that can give rise to
mild scaling, particularly in cold dry climates, as well as other
subtle signs of IV, such as subtle palmar hyperlinearity. Taking
this into account, we showed that IV is actually a semi-domi-
nantly inherited condition, where heterozygous carriers have a
mild IV phenotype and homozygotes or compound heterozy-
gotes have the full-blown classic IV phenotype.9 There is some
degree of overlap in the symptoms depending on lifestyle and
moisturiser use etc., thereby leading to confusion in the inher-
itance patterns seen and reported in the older literature. Thus,
we had finally figured out filaggrin failure and this work was
published early in 2006.9
Early on in the project, we realised that several of the Irish
IV families also had a high incidence of atopic disease – atopic
dermatitis (AD; eczema), food allergy, other allergies, asthma
and hay fever. This is also reflected in the older literature.
Since AD is very common and with IV also being highly
prevalent, this observation could have been explained by the
chance overlap of two frequent disorders within our collection
of families. However, we were able to show by a number of
independent and complementary genetic studies that in fact,
inheritance of the filaggrin loss-of-function mutation confers a
high risk of AD and related atopic diseases. Specifically, we
able to obtain statistically significant genetic linkage between
AD and FLG mutations within our collection of families when
leaving the IV phenotype out of the equation.11 We were also
able to show using case-control genetic analysis that FLG null
mutations were greatly enriched in collections of AD patients
compared to ethnically-matched control populations.11 In the
latter studies, we obtained highly significant associations for
each of the two FLG mutations and when these data were
combined and analysed together, this gave statistical signifi-
cance that was several orders of magnitude higher.
Interestingly, one of studies involved a cohort of children
ascertained initially for asthma.11 About half of these patients
also had a history of eczema. The FLG mutations were shown
to be a major genetic risk factor for asthma per se, but further
analysis revealed that all of the observed association was with
asthma plus eczema group, where as the asthma-only group
showed no FLG association.11 This result demonstrated that
there are at least two forms asthma – one driven via an
eczema/skin barrier pathomechanism and the other driven by
some other unknown mechanism(s). Since filaggrin is not
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Figure 2. Filaggrin deficiency correlates with eczema risk. People
carrying two FLG null mutations express zero filaggrin protein in their
epidermis (bottom panel) and have a massive odds ratio of > 150,
meaning that essentially all of these individuals get eczema.
Heterozygous carriers of a null mutation have about 50% of the
normal amount of filaggrin in their skin and have a high risk (8 9 )
of developing eczema. Finally, even within the so-called normal
population, there is a  10% variation in the amount of filaggrin
produced (due to a subtle type of sequence variation). People
expressing about 90% of the normal amount of filaggrin have a small
but significant eczema risk. In contrast, people expressing more than
the average amount of filaggrin in their epidermis (110%), show a
40% protection from eczema (odds ratio 06). Thus, there is a strong
correlation between the degree of genetically determined filaggrin
deficency and the likelihood of developing eczema. Risks quoted here
come from our original studies of filaggrin in AD10,14 and are higher
than those reported in meta-analyses, where in many studies only a
few mutations are taken into account due to the difficulty in analysing
this gene.
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expressed in the airway epithelia outside of the hair-bearing
outer nasal cavity (which is essentially epidermis), this led to
the hypothesis that filaggrin deficiency leads to atopy via per-
cutaneous antigen/allergen priming, which causes develop-
ment of a systemic allergic immune reaction, which can then
later manifest in other organ system remote from the skin,
such as lung. In keeping with this, genetic associations of the
FLG mutations were reported with hay fever and food allergy
– additional phenotypic markers of the atopic diathesis.1 To
prove this hypothesis experimentally, we turned to animal
models, where we identified the causative mutation in a natu-
ral filaggrin mutant mouse known as flaky tail.12 Using these
animals, we were able to show that filaggrin deficiency allows
allergens cross the epidermis and trigger Th-2 allergic immu-
nity. Thus, the skin barrier hypothesis of eczema was estab-
lished beyond all doubt and has become a widely accepted
dogma in dermatology.
Importantly, our findings were quickly and widely repli-
cated across many studies of Caucasian AD patients and our
initial publication, in March 2006, is currently the most cited
paper in dermatology.11 We went on to develop techniques to
re-sequence the entire filaggrin gene and used these methods
to identify common and rare mutations in many different
human populations.10 These mutations were causative for IV
in these other ethnic groups13 and also strongly associated
with AD across many populations, establishing filaggrin as the
major genetic risk factor for AD and atopy. More recently, we
showed that within the so-called ‘normal’ population, a more
subtle size variation in the FLG gene is also involved in eczema
risk, entirely independent of the loss-of-function mutations.14
The impact of the filaggrin story was far-reaching. The pre-
vailing hypothesis in the AD field previously was that atopy is
due to an ‘overactive’ Th-2 immune system. While Th-2
immunity is clearly the major mediator in the disease process,
our work has shown that an important, if not essential, pri-
mary event is skin barrier deficiency. Although inherited filag-
grin deficiency represents one route to a defective barrier,
there are clearly others still to be worked out and this remains
a fertile field within dermatology research. While the role of
the barrier and the Th-2 immune system are beyond question,
a big unanswered question concerns the identity of the envi-
ronmental trigger factors that drive the disease. In other
words, exactly what is it out there in the environment that
enters the body via a ‘leaky’ skin barrier and triggers the Th-2
response? This may be the key to understanding another
conundrum in the atopy field – why has eczema and allergy
steadily increased in prevalence since the Second World War?
Has this environmental trigger factor or factors increased over
recent decades? Even more importantly – how can we reverse
it?
A current focus of our research is to look for ways to
improve skin barrier function pharmacologically and to this
end, we are applying the state-of-the-art drug discovery infras-
tructure that has become accessible to academia in recent years
to the problem, with the longer term aim of translating the
filaggrin discovery into direct patient benefit.
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